Tradestie Institutional Equity Comparison Engine

BCAX vs AVBP โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BCAX Overall Edge

BCAX Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Bicara Therapeutics Inc. Common Stock (BCAX) driven by superior Growth & Margin, Momentum & Technical while AVBP counters with relative strength in Options & Structure. Fundamentally, BCAX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus AVBP at N/M Forward P/E and -3620.0% operating margin (+0.0% YoY). In options structure, BCAX sits in BREAKDOWN (23rd %ile IV; Dealer Gamma Walls on Pro) against AVBP sits in BREAKDOWN (6th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
BCAX N/M vs AVBP N/M Fwd P/E
Growth & Margin Winner BCAX
Op Margin 0.0% vs -3620.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner BCAX
1Y -32.8% vs -39.1% ยท 52W Pos 7% vs 2%
Options & Structure Winner AVBP
BREAKDOWN (23rd %ile IV) vs BREAKDOWN (6th %ile IV)
BCAX NASDAQ
Bicara Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$9.58
-4.39% 1D
Market Cap $671.2M
1M Return -42.91%
1Y Return -32.82%
Forward P/E N/M
Unified AI Score
52.1 / 100 HOLD
Tech 58.0 Fund 66.0 Flow 68.0 Mom 64.0
AVBP NASDAQ
ArriVent BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$11.98
-7.92% 1D
Market Cap $676.0M
1M Return -28.09%
1Y Return -39.13%
Forward P/E N/M
Unified AI Score
43.7 / 100 HOLD
Tech 33.0 Fund 57.0 Flow 68.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BCAX -32.82% AVBP -39.13% Spread: +6.31 pp (BCAX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BCAX TTM Op. Margin: 0.0% AVBP TTM Op. Margin: -3620.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BCAX vs AVBP. Trailing 12-month operating profitability (BCAX 0.0% vs AVBP -3620.0%) and valuation multiples (BCAX N/M vs AVBP N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BCAX (3) vs AVBP (2)
Institutional Metric BCAX AVBP Criterion Row Winner
Market Capitalization Scale $671.2M $676.0M Larger Scale Tie
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% -3620.0% Higher Margin BCAX
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -54.2% -48.7% Higher ROE AVBP
52-Week Range Position Momentum 7% ($8โ€“$31) 2% ($11โ€“$36) Stronger Trend BCAX
Beta / 30D Volatility Risk Regime 1.41ฮฒ ยท 184% Vol 1.27ฮฒ ยท 128% Vol Lower Realized Risk AVBP
Unified Institutional Score Composite Signal 52.1 / 100 (HOLD) 43.7 / 100 (HOLD) Higher Composite BCAX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BCAX vs AVBP Buy Guide
BCAX BREAKDOWN
93d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live BCAX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AVBP BREAKDOWN
102d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live AVBP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BCAX nor AVBP registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.